RecruitingPhase 3NCT03394365
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Sponsor: Pierre Fabre Medicament
Duarte, CA · La Jolla, CA · Loma Linda, CA · +37 more sites